Live Feeds
● LIVE Updated 1h ago Β· 14 sources tracked

Eli Lilly lifts revenue outlook as weight-loss shot demand soars, shares jump

Eli Lilly raised its annual revenue forecast by $5 billion and beat third-quarter profit estimates due to surging demand for its obesity treatment Zepbound and diabetes drug Mounjaro. The company reported robust third-quarter sales driven by GLP-1 treatments, though it trimmed its profit view due to deal charges. Shares jumped following the earnings report as financial executives look toward the next growth engine and evaluate the Medicare Bridge boon.

πŸŽ™οΈ

Listen to Live Briefing

Real-time synthesized voice briefing Β· Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (14)
⚑ Key Developments & Real-Time Context
Text size:
  • βœ“ Eli Lilly raised its full-year revenue forecast by $5 billion on October 29.
  • βœ“ Sales of obesity drug Zepbound and diabetes treatment Mounjaro surged during the third quarter.
πŸ›‘οΈ Source Corroboration: 14 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Eli Lilly increased its full-year revenue forecast by $5 billion and reported strong third-quarter earnings driven by high demand for Zepbound and Mounjaro.

Live updates

  1. Eli Lilly Lifts Sales Forecast on Soaring Weight-Loss Drug Demand

    Eli Lilly raised its annual revenue forecast by $5 billion and beat third-quarter profit estimates due to surging demand for its obesity treatment Zepbound and diabetes drug Mounjaro. The company reported robust third-quarter sales driven by GLP-1 treatments, though it trimmed its profit view due to deal charges. Shares jumped following the earnings report as financial executives look toward the next growth engine and evaluate the Medicare Bridge boon.

    Why it matters

    Pharmaceutical manufacturers face intense global demand for incretin-based therapies designed to treat diabetes and obesity. Strong sales of these blockbuster medications continue to reshape pharmaceutical earnings and corporate growth strategies. Ongoing corporate transactions and acquisition charges also impact bottom-line financial views despite record-breaking top-line revenue expansions.

    What is confirmed

    • Eli Lilly raised its full-year revenue forecast by $5 billion on October 29.
    • Sales of obesity drug Zepbound and diabetes treatment Mounjaro surged during the third quarter.

    What to watch next

    • Updates on the Medicare Bridge program impact on GLP-1 sales
    • Further corporate disclosures regarding deal charges and profit views
    • Quarterly sales figures for Zepbound and Mounjaro
    Sources used for this update (13)
    1. consent.yahoo.com β€” Latest news and current events updates | Yahoo News Singapore
    2. www.marketscreener.com β€” Global Stocks Fall on Higher Oil Prices, AI Pullback | MarketScreener
    3. contents.premium.naver.com β€” [μž μ˜·μž…κ³  κ²½μ œκ³΅λΆ€] 세계 무역지도λ₯Ό λ°”κΏ€ 사건!
    4. CNBC β€” Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand
    5. WSJ β€” Eli Lilly Revenue Climbs on Demand for Mounjaro, Zepbound
    6. Reuters β€” Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges
    7. Fierce Pharma β€” Lilly breaks down Medicare Bridge boon as GLP-1 sales drive another guidance lift
    8. Barron's β€” Eli Lilly Stock Jumps on Monster Earnings as Finance Chief Eyes Next Growth Engine
    9. www.cnbc.com β€” Eli Lilly (LLY) earnings Q3 2026 - CNBC
    10. www.fool.com β€” After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock?
    11. www.devdiscourse.com β€” Reuters Health News Summary
    12. finance.yahoo.com β€” Eli Lilly lifts revenue outlook as weight-loss shot demand ...
    confidence 100%
πŸ“Š

Community Sentiment: How do you assess this situation?

Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community